Amide-Linked Polymer Conjugates for Protein Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for functionalizing large biological entities like proteins and antibodies with polymers, such as PEGylation, are limited in their ability to enhance plasma half-life and hemocompatibility, and existing ATRP processes lack versatility in solvent-free conditions and efficient conjugation reactions.
Innovation Solution
A new process involving an amide bond forming step between a biologically active starting material and a reagent with a polymer chain, using activating agents like carbodiimides, to create a conjugate that can initiate atom or group transfer radical polymerization, particularly in protic solvents like water, allowing for the formation of hydrophilic polymer conjugates with enhanced properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If PEGylation is used to modify biological entities, then plasma half-life is improved, but hemocompatibility enhancement is limited
Solution Approach 1:
The patent changes the chemical parameters of the polymer modification by using phosphorylcholine-based polymers instead of conventional PEG. This parameter change enables simultaneous improvement of plasma half-life and hemocompatibility, as the phosphorylcholine groups provide both prolonged circulation and enhanced blood compatibility through reduced opsonisation and renal clearance
Solution Approach 2:
The invention creates composite biological entities by conjugating polymers with phosphorylcholine groups to biological molecules. This composite structure combines the benefits of prolonged plasma half-life from the polymer conjugation with the hemocompatibility enhancement from the phosphorylcholine groups, achieving multiple therapeutic effects simultaneously
2Productivity
If conventional ATRP processes are used, then polymerization can occur, but versatility in solvent-free conditions is limited
Solution Approach 1:
The patent changes the solvent parameter from conventional organic solvents to protic solvents including water. This parameter change enables ATRP to proceed under solvent-free or aqueous conditions, significantly enhancing the versatility and adaptability of the polymerization process while maintaining high productivity through controlled radical polymerization mechanisms
3Stability of the object's composition
If amide bond forming step is used for conjugation, then solubility and stability are improved, but reaction complexity increases
Solution Approach 1:
The invention uses activating agents such as carbodiimides as intermediaries to facilitate the amide bond formation between the biologically active compound and the polymer. This intermediary approach simplifies the conjugation process by providing a reliable coupling mechanism that enhances conjugate stability without requiring complex reaction conditions or multiple steps
Solution Approach 2:
The patent changes the reaction parameter by utilizing activating agents that promote amide bond formation under mild conditions. This parameter change enables efficient conjugation with high stability while reducing the overall complexity of the process, as the activating agents facilitate the reaction without requiring extreme temperatures, pressures, or multiple sequential steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process enables the formation of biologically active conjugates with controlled solubility, bioavailability, stability, and delivery characteristics, particularly suitable for proteins and antibodies, by forming amide-linked conjugates that can initiate polymerization reactions, thereby improving the plasma half-life and hemocompatibility of biological entities.
Implementation Method 1
a conjugation step in which a biologically active starting material of the general formula I is reacted in an amide bond forming step with a reagent of the general formula II to form an amide-linked conjugate
Implementation Method 2
The modified drug is capable of initiating an atom transfer radical polymerisation (ATRP) with monomers such as 2-methacryloyloxyethyl-2′-trimethylammonium ethyl phosphate inner salt
Implementation Method 3
whereby the residual group derived from the initiator may be used in subsequent reactions
Data Source
AI summary
An initiator for the terminal group of the polymer product of an atom or group radical transfer polymerisation has an activated carboxyl or an amine group which is reacted with an amine or carboxyl (respectively) group containing biologically active compound. The initiator is preferably 4-(3-(2-bromo, 2-methyl-propionate)phenyl)-propionic acid N-hydroxysuccinimide ester or 2-bromo, 2-methyl-propionic acid N-hydroxysuccinimide ester. The monomers preferably comprise a zwitterionic monomer such as 2-methacryloxyethyl-2′-trimethyl ammoniumethyl phosphate inner salt.